Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus METRONIDAZOLE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus METRONIDAZOLE IN PLASTIC CONTAINER.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs METRONIDAZOLE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
None Documented
None Documented
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic